Bio Rad Financials

BIO Stock  USD 325.58  1.89  0.58%   
Based on the measurements of operating efficiency obtained from Bio Rad's historical financial statements, Bio Rad Laboratories may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Bio Rad's Retained Earnings are very stable compared to the past year. As of the 22nd of November 2024, Non Current Assets Total is likely to grow to about 9.7 B, while Total Current Liabilities is likely to drop about 338.4 M. Key indicators impacting Bio Rad's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.130.1361
Sufficiently Down
Slightly volatile
Current Ratio6.125.8308
Sufficiently Up
Slightly volatile
Investors should never underestimate Bio Rad's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bio Rad's cash flow, debt, and profitability to make informed and accurate decisions about investing in Bio Rad Laboratories.

Cash And Equivalents

549.92 Million

  
Understanding current and past Bio Rad Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bio Rad's financial statements are interrelated, with each one affecting the others. For example, an increase in Bio Rad's assets may result in an increase in income on the income statement.

Bio Rad Earnings Geography

Bio Rad Stock Summary

Bio Rad competes with Tandem Diabetes, DexCom, Inspire Medical, Penumbra, and CONMED. Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California. Bio-Rad Laboratories operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 8200 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNew York Stock Exchange
ISINUS0905722072
CUSIP090572207
LocationCalifornia; U.S.A
Business Address1000 Alfred Nobel
SectorLife Sciences Tools & Services
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.bio-rad.com
Phone510 724 7000
CurrencyUSD - US Dollar

Bio Rad Key Financial Ratios

Bio Rad Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets8.0B13.0B17.8B13.5B12.3B12.9B
Other Current Liab158.5M354.0M404.9M312.2M301.6M316.6M
Net Debt(220.9M)(648.1M)(459.8M)764.0M1.0B1.1B
Retained Earnings5.5B9.3B13.5B9.9B9.3B9.7B
Cash660.7M662.2M470.8M434.2M404.0M257.1M
Net Receivables392.7M419.4M423.5M494.6M489.0M272.4M
Inventory554.0M622.3M572.2M719.3M780.5M819.5M
Other Current Assets113.3M97.5M124.8M153.3M171.7M92.3M
Total Liab2.3B3.1B4.1B3.9B3.6B3.7B
Total Current Assets2.2B2.1B2.0B3.2B3.0B3.2B
Short Term Debt426.2M38.3M36.9M36.8M40.9M33.9M
Accounts Payable287.1M139.5M141.9M135.0M144.6M116.6M
Intangible Assets145.5M199.5M253.9M332.1M320.5M188.7M
Other Assets40.3M13K82K94.6M85.1M71.4M
Long Term Debt13.6M12.3M10.5M1.2B1.2B1.3B
Good Will264.1M291.9M347.3M406.5M413.6M339.1M
Treasury Stock(38.4M)(99.9M)(106.3M)(263.6M)(237.2M)(225.4M)
Other Liab1.2B2.4B3.4B2.0B2.3B2.4B
Net Tangible Assets5.8B9.9B13.1B9.2B10.6B11.1B
Capital Surpluse410.0M429.4M441.7M447.5M514.6M366.5M

Bio Rad Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense23.4M21.9M1.6M38.1M49.4M51.9M
Total Revenue2.3B2.5B2.9B2.8B2.7B1.4B
Gross Profit1.3B1.4B1.6B1.6B1.4B769.3M
Operating Income229.7M411.0M489.4M482.6M383.8M403.0M
Ebit229.7M4.9B5.5B(4.7B)(800.7M)(760.6M)
Ebitda390.0M5.1B5.6B(4.5B)(608.3M)(577.9M)
Cost Of Revenue1.1B1.1B1.3B1.2B1.2B1.3B
Income Before Tax2.3B4.9B5.4B(4.7B)(850.1M)(807.6M)
Net Income1.8B3.8B4.3B(3.6B)(637.3M)(605.5M)
Income Tax Expense502.4M1.1B1.2B(1.1B)(212.8M)(202.1M)
Research Development202.7M226.6M271.7M256.9M226.9M161.8M
Tax Provision502.4M1.1B1.2B(1.1B)(27.9M)(26.5M)
Interest Income30.5M4.5B4.9B58M96.4M91.6M
Net Interest Income7.1M(21.9M)(1.6M)19.9M47.6M50.0M

Bio Rad Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory24.2M(52.1M)46.1M(158.8M)(46.3M)(44.0M)
Change In Cash228.5M4.5M(196.0M)(36.6M)(30.2M)(28.7M)
Free Cash Flow359.4M476.4M535.7M80.3M218.3M229.2M
Depreciation134.2M138.1M133.8M137.3M192.4M202.0M
Other Non Cash Items(1.5B)(3.4B)(3.7B)5.3B1.1B1.1B
Capital Expenditures98.5M98.9M120.8M114.2M156.7M84.5M
Net Income1.8B3.8B4.2B(3.6B)(637.3M)(605.5M)
End Period Cash Flow662.7M667.1M471.1M434.5M404.4M286.4M
Change To Netincome(2.0B)(3.5B)(3.8B)5.3B4.7B5.0B
Change Receivables31.7M21.5M35.3M68.2M78.4M82.3M
Net Borrowings(1.1M)(426.9M)(3.0M)1.2B1.4B1.4B
Investments(119.3M)119.6M(538.2M)(994.2M)(110.5M)(116.1M)

Bio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bio Rad's current stock value. Our valuation model uses many indicators to compare Bio Rad value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio Rad competition to find correlations between indicators driving Bio Rad's intrinsic value. More Info.
Bio Rad Laboratories is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Bio Rad's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Rad's earnings, one of the primary drivers of an investment's value.

Bio Rad's Earnings Breakdown by Geography

Bio Rad Laboratories Systematic Risk

Bio Rad's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bio Rad volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Bio Rad Laboratories correlated with the market. If Beta is less than 0 Bio Rad generally moves in the opposite direction as compared to the market. If Bio Rad Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bio Rad Laboratories is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bio Rad is generally in the same direction as the market. If Beta > 1 Bio Rad moves generally in the same direction as, but more than the movement of the benchmark.

Bio Rad Thematic Clasifications

Bio Rad Laboratories is part of Measuring and Control Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
Measuring and Control EquipmentView
This theme covers USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Bio Rad Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Rad's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bio Rad growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.15

At this time, Bio Rad's Price Earnings To Growth Ratio is very stable compared to the past year.

Bio Rad November 22, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Bio Rad help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bio Rad Laboratories. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bio Rad Laboratories based on widely used predictive technical indicators. In general, we focus on analyzing Bio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bio Rad's daily price indicators and compare them against related drivers.
When determining whether Bio Rad Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Rad's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Rad Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Rad Laboratories Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bio Rad Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Rad. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Rad listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
5.412
Earnings Share
(28.09)
Revenue Per Share
90.815
Quarterly Revenue Growth
0.028
Return On Assets
0.0186
The market value of Bio Rad Laboratories is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Rad's value that differs from its market value or its book value, called intrinsic value, which is Bio Rad's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Rad's market value can be influenced by many factors that don't directly affect Bio Rad's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Rad's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Rad is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Rad's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.